Will Boehringer Ingelheim’s ‘nintedanib’ become a victim of the risk sharing system?
As Ildong Pharmaceutical’s idiopathic pulmonary fibrosis(IPF) treatment, ‘Pirespa(generic name: pirfenidone)’ has acquired the health insurance application, its follow-up substance, Boehringer Ingelheim’s nintedanib, is in trouble.
According to the revision of the drug insurance benefit list and...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
